Inhibitory effect of atorvastatin on the cell growth of cardiac myxomas via the PTEN and PHLPP2 phosphatase signaling pathway

Wu,Xing-Li; Yang,Ding-You; Tan,Duan-Jun; Yao,Heng-Chen; Chai,Wenhui; Pen,Li

doi:10.3892/or.2013.2501

Inhibitory effect of atorvastatin on the cell growth of cardiac myxomas via the PTEN and PHLPP2 phosphatase signaling pathway

Authors:
- Xing-Li Wu
- Ding-You Yang
- Duan-Jun Tan
- Heng-Chen Yao
- Wenhui Chai
- Li Pen
View Affiliations

Affiliations: Institute of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, P.R. China, Department of Traditional Chinese Medicine, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing, P.R. China, Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA, Department of Cardiology, Liaocheng City Hospital, Shandong, P.R. China, Department of Geriatric Cardiology, Changji City Hospital, Xinjiang, P.R. China
Published online on: May 28, 2013 https://doi.org/10.3892/or.2013.2501
Pages: 757-762

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin-like growth factor 1 (IGF-1) is a molecule with strong proliferative effects, and statins have been reported to exhibit antitumor effects based on clinical and experimental studies. However, their effects on cardiac myxoma (CM) cells and the underlying signaling mechanism(s) are largely unknown. Therefore, we investigated whether the protein/lipid phosphatases and tensin homolog deleted on chromosome ten (PTEN) and pleckstrin homology domain leucine-rich repeat phosphatase 1 and 2 (PHLPP1 and 2) are involved in the proliferative effect of IGF-1 on CM cells and the pharmacological impact of atorvastatin. The activity of PTEN and PHLPPs was determined using specific substrate diC16PIP3 and pNPP. We found that IGF-1 enhanced CM cell proliferation and inhibited both PTEN and PHLPP2 activity in a concentration- and time-dependent manner. Atorvastatin acted counter to IGF-1 and reversed the above effects mediated by IGF-1. Both IGF-1 and atorvastatin did not affect the activity of PHLPP1 and the protein expression of the three phosphatases. The results suggest that IGF-1 may exert its proliferative effects by negatively regulating the PTEN/PHLPP2 signaling pathway in CM cells, and atorvastatin may be a potential drug for the treatment of CM by enhancing the activity of PTEN and PHLPP2.

View Figures

View References

1	Roschkov S, Rebeyka D, Mah J and Urquhart G: The dangers of cardiac myxomas. Prog Cardiovasc Nurs. 22:27–30. 2007. View Article : Google Scholar : PubMed/NCBI
2	Wilkes D, McDermott DA and Basson CT: Clinical phenotypes and molecular genetic mechanisms of Carney complex. Lancet Oncol. 6:501–508. 2005. View Article : Google Scholar : PubMed/NCBI
3	Figueroa-Torres Y, Martínez-Ojeda JA, Franqui-Rivera H, et al: Benign cardiac neoplasms: the experience at the Cardiovascular Center of Puerto Rico and the Caribbean. PR Health Sci J. 27:373–376. 2008.PubMed/NCBI
4	Wu X, Yang D, Yang Z, et al: Clinical characteristics and long term post-operative outcome of cardiac myxoma. EXCLI J. 11:240–249. 2012.
5	Barh D, Kumar A, Chatterjee S and Liloglou T: Molecular features, markers, drug targets, and prospective targeted therapeutics in cardiac myxoma. Curr Cancer Drug Targets. 9:705–716. 2009. View Article : Google Scholar : PubMed/NCBI
6	Chu PH, Jung SM, Yeh TS, et al: MUC1, MUC2 and MUC5AC expressions in cardiac myxoma. Virchows Arch. 446:52–55. 2005. View Article : Google Scholar : PubMed/NCBI
7	Orlandi A, Ciucci A, Ferlosio A, et al: Increased expression and activity of matrix metalloproteinases characterize embolic cardiac myxomas. Am J Pathol. 166:1619–1628. 2005. View Article : Google Scholar : PubMed/NCBI
8	Sakamoto H, Sakamaki T, Kanda T, et al: Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells. Circ J. 68:488–493. 2004. View Article : Google Scholar : PubMed/NCBI
9	Fujisawa H, Koide N, Kono T, et al: Expression of basic fibroblast growth factor and its receptor-1 in cardiac myxoma. J Cardiovasc Surg. 43:589–594. 2002.PubMed/NCBI
10	Amano J, Kono T, Wada Y, et al: Cardiac myxoma: its origin and tumor characteristics. Ann Thorac Cardiovasc Surg. 9:215–221. 2003.PubMed/NCBI
11	Uzoh CC, Holly JMP, Biernacka KM, et al: Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer. 104:1587–1593. 2011. View Article : Google Scholar : PubMed/NCBI
12	Rzucidlo EM: Signaling pathways regulating vascular smooth muscle cell differentiation. Vascular. 17(Suppl 1): S15–S20. 2009. View Article : Google Scholar : PubMed/NCBI
13	Perks C: The role of insulin-like growth factor binding proteins. Neuroendocrinology. 83:154–160. 2006. View Article : Google Scholar : PubMed/NCBI
14	Mateus C, Palangié A, Franck N, et al: Heterogeneity of skin manifestations in patients with Carney complex. J Am Acad Dermatol. 59:801–810. 2008. View Article : Google Scholar : PubMed/NCBI
15	Raff SB, Carney JA, Krugman D, et al: Prolactin secretion abnormalities in patients with the ‘syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). J Pediatr Endocrinol Metab. 13:373–379. 2000.
16	Kurtkaya-Yapicier O, Scheithauer BW, Carney JA, et al: Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastruct Pathol. 26:345–353. 2002. View Article : Google Scholar
17	Wahdan-Alaswad RS, Song K, Krebs T, et al: Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res. 70:9106–9117. 2012. View Article : Google Scholar : PubMed/NCBI
18	Grimberg A: Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 2:630–635. 2003. View Article : Google Scholar : PubMed/NCBI
19	Liu B, Lee KW, Anzo M, et al: Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene. 26:1811–1819. 2007. View Article : Google Scholar : PubMed/NCBI
20	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
21	Waalkes S, Simon P, Hennenlotter J, et al: Altered expression of Akt signaling pathway parameters in prostate needle biopsies derived from benign, adjacent and cancerous tissue. Oncol Rep. 23:1257–1260. 2010.PubMed/NCBI
22	Falbo V, Floridia G, Censi F, et al: Three cases of rare salivary gland tumours: a molecular study of TP53, CDKN2A/ARF, RAS, BRAF, PTEN, MAPK2 and EGFR genes. Oncol Rep. 26:3–11. 2011.PubMed/NCBI
23	Tserga A, Michalopoulos NV, Levidou G, et al: Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol Rep. 27:1630–1638. 2012.PubMed/NCBI
24	Bouali S, Chrétien AS, Ramacci C, et al: PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep. 21:731–735. 2009.PubMed/NCBI
25	Jang K, Kim M, Seo HS, et al: PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation. Oncol Rep. 24:787–793. 2010.PubMed/NCBI
26	Garcia JA and Danielpour D: Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 7:1347–1354. 2008. View Article : Google Scholar : PubMed/NCBI
27	Wu XL, Yang DY, Yang ZS, et al: Effect of IGF-1 on PI3K/PTEN signal pathway in vascular smooth muscle cell. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 20:259–262. 2004.(In Chinese).
28	Brognard J, Sierecki E, Gao T, et al: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 25:917–931. 2007. View Article : Google Scholar : PubMed/NCBI
29	Gao T, Brognard J and Newton AC: The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem. 283:6300–6311. 2008. View Article : Google Scholar : PubMed/NCBI
30	McCarty MF: Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses. 56:12–16. 2001. View Article : Google Scholar : PubMed/NCBI
31	Martínez-González J, Viñals M, Vidal F, et al: Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells. Atherosclerosis. 135:213–223. 1997.PubMed/NCBI
32	Miraglia E, Högberg J and Stenius U: Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. Int J Oncol. 40:867–875. 2012.PubMed/NCBI
33	Duncan RE, El-Sohemy A and Archer MC: Statins and cancer development. Cancer Epidemiol Biomarkers Prev. 14:1897–1898. 2005. View Article : Google Scholar : PubMed/NCBI
34	Bonovas S, Filioussi K, Tsavaris N, et al: Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 24:4808–4817. 2006. View Article : Google Scholar : PubMed/NCBI
35	Chan KK, Oza AM and Siu LL: The statins as anticancer agents. Clin Cancer Res. 9:10–19. 2003.
36	Lutski M, Shalev V, Porath A and Chodick G: Continuation with statin therapy and the risk of primary cancer: a population-based study. Prev Chronic Dis. 9:E1372012. View Article : Google Scholar : PubMed/NCBI
37	Brown M, Hart C, Tawadros T, et al: The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer. 106:1689–1696. 2012. View Article : Google Scholar : PubMed/NCBI
38	Parada B, Reis F, Pinto A, et al: Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci. 13:8482–8499. 2012. View Article : Google Scholar : PubMed/NCBI
39	Lai SW, Liao KF, Lai HC, et al: Atorvastatin correlates with decreased risk of esophageal cancer: a population-based case-control study from Taiwan. Libyan J Med. 7:188302012.PubMed/NCBI
40	Miyamoto S, Purcell NH, Smith JM, et al: PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res. 107:476–484. 2010. View Article : Google Scholar : PubMed/NCBI
41	Nitsche C, Edderkaoui M, Moore RM, et al: The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology. 142:377–387. 2012. View Article : Google Scholar : PubMed/NCBI
42	Mulholland DJ, Tran LM, Li Y, et al: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 19:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
43	Lee JK, Edderkaoui M, Truong P, et al: NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases. Gastroenterology. 133:1637–1648. 2007. View Article : Google Scholar : PubMed/NCBI
44	Mistafa O, Ghalali A, Kadekar S, et al: Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J Biol Chem. 285:27900–27910. 2010. View Article : Google Scholar